Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 12.7% After Earnings Beat

Key Points

• Praxis Precision Medicines shares rose 12.7% after the company reported a quarterly loss of $3.23 per share, narrower than analysts’ consensus estimate of a $3.54 loss.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $630.42; individual targets cited range from $514 to $945.
• Institutional investors and hedge funds own 67.84% of the company. Orbimed Advisors increased its stake by 82.5% in the first quarter.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) shot up 12.7% during mid-day trading on Monday following a better than expected earnings announcement. The company traded as high as $310.00 and last traded at $312.9850. Approximately 224,104 shares traded hands during trading, a decline of 52% from the average daily volume of 463,969 shares. The stock had previously closed at $277.62.

The company reported ($3.23) EPS for the quarter, beating analysts' consensus estimates of ($3.54) by $0.31.

Analysts Set New Price Targets

PRAX has been the subject of a number of recent analyst reports. Robert W. Baird set a $514.00 target price on shares of Praxis Precision Medicines in a research report on Friday, August 7th. UBS Group started coverage on shares of Praxis Precision Medicines in a research report on Wednesday, October 14th. They issued a "buy" rating and a $706.00 price target on the stock. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $945.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, August 17th. Piper Sandler reiterated an "overweight" rating on shares of Praxis Precision Medicines in a research report on Monday, July 13th. Finally, Wall Street Zen cut shares of Praxis Precision Medicines from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $630.42.

Institutional Investors Weigh In On Praxis Precision Medicines

Several large investors have recently added to or reduced their stakes in PRAX. Seven Fleet Capital Management LP acquired a new stake in shares of Praxis Precision Medicines in the 2nd quarter valued at about $2,524,000. Readystate Asset Management LP bought a new position in Praxis Precision Medicines in the second quarter worth approximately $3,531,000. Swiss National Bank boosted its holdings in Praxis Precision Medicines by 15.3% in the first quarter. Swiss National Bank now owns 46,700 shares of the company's stock worth $15,046,000 after acquiring an additional 6,200 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Praxis Precision Medicines in the second quarter valued at approximately $2,698,000. Finally, Orbimed Advisors LLC grew its stake in Praxis Precision Medicines by 82.5% in the first quarter. Orbimed Advisors LLC now owns 172,500 shares of the company's stock valued at $55,578,000 after acquiring an additional 78,000 shares during the period. Institutional investors and hedge funds own 67.84% of the company's stock.

Praxis Precision Medicines Price Performance

The stock has a market cap of $8.60 billion, a P/E ratio of -23.82 and a beta of 2.85. The company has a fifty day moving average price of $291.73 and a 200 day moving average price of $313.72.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity.

Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.